Healthcare Market Research Reports & Industry Analysis

Healthcare refers to the field associated with maintaining or restoring patients’ health. These days’ Healthcare Industry falls into a lashing of discrete sub-sectors, and ancillary goods and services. Ranging from therapeutic equipment to medicinal drugs, medical tourism to sickness insurance, the Healthcare Market has been one of the most swiftly expanding sectors within the globe’s economic system.

Global Healthcare spending contributes close to 10% to the whole world’s GDP, though it varies noticeably with geography. Thus, the Western world’s average healthcare costs are far greater in contrast to those in the developing economies. North America alone is in charge of circa a half of the world’s overall spending on healthcare services. With budgets curtailments and growing costs, technology advances are increasingly taking a new meaning in the global Healthcare universe.

The research reports offer comprehensive insights into the market sizing, structure and dynamics of the Healthcare Industry based on various geographies, as well as in-depth market segmentation. The research reports incorporated in this Catalogue closely investigate the competition in the Healthcare Market, besides profiling countless market participants. Moreover, tomorrow's healthcare-related challenges are addressed, as well as projections into the future are provided in the research reports.

Publications found: 71,946
Sort by:

Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) Drugs in Development by Therapy A...

May 2022 47 pages

Cells Expressing Vascular Endothelial Growth Factor Receptor 2 (Fetal Liver Kinase 1 or Kinase Insert Domain Receptor or Protein Tyrosine Kinase Receptor flk 1 or VEGFR2 or CD309 or KDR or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Vascular Endothelial Growth Factor Receptor 2 (Fetal Liver Kinase 1 or Kinase Insert Domain Receptor or Protein Tyrosine Kinase Receptor flk 1 or VEGFR2 or CD309 or KDR or EC 2.7.10.1...

May 2022 36 pages

Ceramide Glucosyltransferase (Glucosylceramide Synthase or GLCT 1 or UDP Glucose:N Acylsphingosine D Glucosyltransferase or UDP Glucose Ceramide Glucosyltransferase or UGCG or EC 2.4.1.80) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Ceramide Glucosyltransferase (Glucosylceramide Synthase or GLCT 1 or UDP Glucose:N Acylsphingosine D Glucosyltransferase or UDP Glucose Ceramide Glucosyltransferase or UGCG or EC 2.4.1.80) Drugs in De...

May 2022 42 pages

Cholinesterase (Butyrylcholinesterase or Acylcholine Acylhydrolase or Choline Esterase II or Pseudocholinesterase or BCHE or EC 3.1.1.8) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cholinesterase (Butyrylcholinesterase or Acylcholine Acylhydrolase or Choline Esterase II or Pseudocholinesterase or BCHE or EC 3.1.1.8) Drugs in Development by Therapy Areas and Indications, Stages,...

May 2022 39 pages

Coagulation Factor VII (Proconvertin or Serum Prothrombin Conversion Accelerator or SPCA or Eptacog Alfa or F7 or EC 3.4.21.21) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Coagulation Factor VII (Proconvertin or Serum Prothrombin Conversion Accelerator or SPCA or Eptacog Alfa or F7 or EC 3.4.21.21) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA,...

May 2022 49 pages

CX3C Chemokine Receptor 1 (Beta Chemokine Receptor Like 1 or CMK BRL1 or Fractalkine Receptor or G Protein Coupled Receptor 13 or V28 or GPR13 or CX3CR1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

CX3C Chemokine Receptor 1 (Beta Chemokine Receptor Like 1 or CMK BRL1 or Fractalkine Receptor or G Protein Coupled Receptor 13 or V28 or GPR13 or CX3CR1) Drugs in Development by Therapy Areas and Indi...

May 2022 37 pages

Cyclin Dependent Kinase 19 (CDC2 Related Protein Kinase 6 or Cell Division Cycle 2 Like Protein Kinase 6 or Cell Division Protein Kinase 19 or Cyclin Dependent Kinase 11 or Death Preventing Kinase or CDK11 or CDK19 or EC 2.7.11.22) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cyclin Dependent Kinase 19 (CDC2 Related Protein Kinase 6 or Cell Division Cycle 2 Like Protein Kinase 6 or Cell Division Protein Kinase 19 or Cyclin Dependent Kinase 11 or Death Preventing Kinase or...

May 2022 40 pages

Cyclin Dependent Kinase 8 (Protein Kinase K35 or Mediator Of RNA Polymerase II Transcription Subunit CDK8 or Cell Division Protein Kinase 8 or Mediator Complex Subunit CDK8 or CDK8 or EC 2.7.11.22 or EC 2.7.11.23) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cyclin Dependent Kinase 8 (Protein Kinase K35 or Mediator Of RNA Polymerase II Transcription Subunit CDK8 or Cell Division Protein Kinase 8 or Mediator Complex Subunit CDK8 or CDK8 or EC 2.7.11.22 or...

May 2022 41 pages

Cysteinyl Leukotriene Receptor 1 (Cysteinyl Leukotriene D4 Receptor or G Protein Coupled Receptor HG55 or HMTMF81 or CYSLTR1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cysteinyl Leukotriene Receptor 1 (Cysteinyl Leukotriene D4 Receptor or G Protein Coupled Receptor HG55 or HMTMF81 or CYSLTR1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, M...

May 2022 42 pages

Cystic Fibrosis Transmembrane Conductance Regulator (ATP Binding Cassette Sub Family C Member 7 or Channel Conductance Controlling ATPase Camp Dependent Chloride Channel or ABCC7 or CFTR or EC 5.6.1.6) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cystic Fibrosis Transmembrane Conductance Regulator (ATP Binding Cassette Sub Family C Member 7 or Channel Conductance Controlling ATPase Camp Dependent Chloride Channel or ABCC7 or CFTR or EC 5.6.1.6...

May 2022 107 pages

Diacylglycerol O Acyltransferase 2 (Diglyceride Acyltransferase 2 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT2 or EC 2.3.1.76 or EC 2.3.1.20) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Diacylglycerol O Acyltransferase 2 (Diglyceride Acyltransferase 2 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT2 or EC 2.3.1.76 or EC 2.3.1.20) Drugs in Development by Therapy Areas and Indicati...

May 2022 35 pages

Dipeptidyl Peptidase 4 (ADABP or Adenosine Deaminase Complexing Protein 2 or T Cell Activation Antigen CD26 or TP103 or CD26 or DPP4 or EC 3.4.14.5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Dipeptidyl Peptidase 4 (ADABP or Adenosine Deaminase Complexing Protein 2 or T Cell Activation Antigen CD26 or TP103 or CD26 or DPP4 or EC 3.4.14.5) Drugs in Development by Therapy Areas and Indicatio...

May 2022 74 pages

DNA (Apurinic or Apyrimidinic Site) Lyase (APEX Nuclease or APEN or Apurinic Apyrimidinic Endonuclease 1 or AP Endonuclease 1 or REF 1 or Redox Factor 1 or APEX1 or EC 4.2.99.18 or EC 3.1.) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

DNA (Apurinic or Apyrimidinic Site) Lyase (APEX Nuclease or APEN or Apurinic Apyrimidinic Endonuclease 1 or AP Endonuclease 1 or REF 1 or Redox Factor 1 or APEX1 or EC 4.2.99.18 or EC 3.1.) Drugs in D...

May 2022 38 pages

DNA (Cytosine 5 ) Methyltransferase 1 (CXXC Type Zinc Finger Protein 9 or DNA Methyltransferase HsaI or MCMT or DNMT1 or EC 2.1.1.37) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

DNA (Cytosine 5 ) Methyltransferase 1 (CXXC Type Zinc Finger Protein 9 or DNA Methyltransferase HsaI or MCMT or DNMT1 or EC 2.1.1.37) Drugs in Development by Therapy Areas and Indications, Stages, MoA...

May 2022 50 pages

E Selectin (CD62 Antigen Like Family Member E or Endothelial Leukocyte Adhesion Molecule 1 or Leukocyte Endothelial Cell Adhesion Molecule 2 or LECAM2 or CD62E or SELE) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

E Selectin (CD62 Antigen Like Family Member E or Endothelial Leukocyte Adhesion Molecule 1 or Leukocyte Endothelial Cell Adhesion Molecule 2 or LECAM2 or CD62E or SELE) Drugs in Development by Therapy...

May 2022 39 pages

E3 Ubiquitin Protein Ligase CBL B (Casitas B Lineage Lymphoma Proto Oncogene b or RING Finger Protein 56 or SH3 Binding Protein CBLB or Signal Transduction Protein CBLB or CBLB or EC 2.3.2.27) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

E3 Ubiquitin Protein Ligase CBL B (Casitas B Lineage Lymphoma Proto Oncogene b or RING Finger Protein 56 or SH3 Binding Protein CBLB or Signal Transduction Protein CBLB or CBLB or EC 2.3.2.27) Drugs i...

May 2022 40 pages

Ectonucleoside Triphosphate Diphosphohydrolase 1 (NTPDase 1 or Ecto ATP Diphosphohydrolase 1 or Ecto Apyrase or Lymphoid Cell Activation Antigen or CD39 or ENTPD1 or EC 3.6.1.5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Ectonucleoside Triphosphate Diphosphohydrolase 1 (NTPDase 1 or Ecto ATP Diphosphohydrolase 1 or Ecto Apyrase or Lymphoid Cell Activation Antigen or CD39 or ENTPD1 or EC 3.6.1.5) Drugs in Development b...

May 2022 45 pages

Egl Nine Homolog 1 (Hypoxia Inducible Factor Prolyl Hydroxylase 2 or Prolyl Hydroxylase Domain Containing Protein 2 or SM 20 or EGLN1 or EC 1.14.11.29) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Egl Nine Homolog 1 (Hypoxia Inducible Factor Prolyl Hydroxylase 2 or Prolyl Hydroxylase Domain Containing Protein 2 or SM 20 or EGLN1 or EC 1.14.11.29) Drugs in Development by Therapy Areas and Indica...

May 2022 39 pages

Endothelial PAS Domain Containing Protein 1 (Basic Helix Loop Helix PAS Protein MOP2 or Class E Basic Helix Loop Helix Protein 73 or HIF 1 Alpha Like Factor or Hypoxia Inducible Factor 2 Alpha or PAS Domain Containing Protein 2 or EPAS1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Endothelial PAS Domain Containing Protein 1 (Basic Helix Loop Helix PAS Protein MOP2 or Class E Basic Helix Loop Helix Protein 73 or HIF 1 Alpha Like Factor or Hypoxia Inducible Factor 2 Alpha or PAS...

May 2022 43 pages

Epidermal Growth Factor Receptor (Proto Oncogene c ErbB 1 or Receptor Tyrosine Protein Kinase erbB 1 or HER1 or ERBB1 or EGFR or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 3,500.00

Epidermal Growth Factor Receptor (Proto Oncogene c ErbB 1 or Receptor Tyrosine Protein Kinase erbB 1 or HER1 or ERBB1 or EGFR or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Sta...

May 2022 259 pages

Epithelial Discoidin Domain Containing Receptor 1 (CD167 Antigen Like Family Member A or Mammary Carcinoma Kinase 10 or Protein Tyrosine Kinase 3A or Protein Tyrosine Kinase RTK 6 or Tyrosine Protein Kinase CAK or CD167a or DDR1 or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Epithelial Discoidin Domain Containing Receptor 1 (CD167 Antigen Like Family Member A or Mammary Carcinoma Kinase 10 or Protein Tyrosine Kinase 3A or Protein Tyrosine Kinase RTK 6 or Tyrosine Protein...

May 2022 42 pages

Eukaryotic Translation Initiation Factor 2 Alpha Kinase 3 (PRKR Like Endoplasmic Reticulum Kinase or Pancreatic eIF2 Alpha Kinase or EIF2AK3 or EC 2.7.11.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Eukaryotic Translation Initiation Factor 2 Alpha Kinase 3 (PRKR Like Endoplasmic Reticulum Kinase or Pancreatic eIF2 Alpha Kinase or EIF2AK3 or EC 2.7.11.1) Drugs in Development by Therapy Areas and I...

May 2022 35 pages

Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) Drugs in Develop...

May 2022 99 pages

Galactocerebrosidase (Galactosylceramidase or Galcerase or Galactocerebroside Beta Galactosidase or Galactosylceramide Beta Galactosidase or GALC or EC 3.2.1.46) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Galactocerebrosidase (Galactosylceramidase or Galcerase or Galactocerebroside Beta Galactosidase or Galactosylceramide Beta Galactosidase or GALC or EC 3.2.1.46) Drugs in Development by Therapy Areas...

May 2022 38 pages

Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC...

May 2022 40 pages

Glycylpeptide N Tetradecanoyltransferase (Myristoyl CoA:Protein N Myristoyltransferase or Peptide N Myristoyltransferase or NMT or EC 2.3.1.97) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Glycylpeptide N Tetradecanoyltransferase (Myristoyl CoA:Protein N Myristoyltransferase or Peptide N Myristoyltransferase or NMT or EC 2.3.1.97) Drugs in Development by Therapy Areas and Indications, S...

May 2022 35 pages

Hemoglobin Subunit Gamma 1 (Gamma Globin or Gamma1 Globin or Hb F Agamma or Hemoglobin Gamma 1 Chain or Hemoglobin Gamma A Chain or HBG1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Hemoglobin Subunit Gamma 1 (Gamma Globin or Gamma1 Globin or Hb F Agamma or Hemoglobin Gamma 1 Chain or Hemoglobin Gamma A Chain or HBG1) Drugs in Development by Therapy Areas and Indications, Stages,...

May 2022 35 pages

Hepatitis B Virus DNA Polymerase (Hepatitis B Virus Reverse Transcriptase or Hepatitis B Virus Ribonuclease H or EC 2.7.7.7 or EC 2.7.7.49 or EC 3.1.26.4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Hepatitis B Virus DNA Polymerase (Hepatitis B Virus Reverse Transcriptase or Hepatitis B Virus Ribonuclease H or EC 2.7.7.7 or EC 2.7.7.49 or EC 3.1.26.4) Drugs in Development by Therapy Areas and Ind...

May 2022 36 pages

Inactive Tyrosine Protein Kinase Transmembrane Receptor ROR1 (Neurotrophic Tyrosine Kinase Receptor Related 1 or ROR1 or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Inactive Tyrosine Protein Kinase Transmembrane Receptor ROR1 (Neurotrophic Tyrosine Kinase Receptor Related 1 or ROR1 or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA...

May 2022 36 pages

Integrin Alpha 5 (CD49 Antigen Like Family Member E or Fibronectin Receptor Subunit Alpha or Integrin Alpha F or VLA 5 or CD49e or ITGA5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Integrin Alpha 5 (CD49 Antigen Like Family Member E or Fibronectin Receptor Subunit Alpha or Integrin Alpha F or VLA 5 or CD49e or ITGA5) Drugs in Development by Therapy Areas and Indications, Stages,...

May 2022 40 pages

Integrin Alpha M (CD11 Antigen Like Family Member B or CR 3 Alpha Chain or Leukocyte Adhesion Receptor MO1 or Neutrophil Adherence Receptor or CD11b or ITGAM) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Integrin Alpha M (CD11 Antigen Like Family Member B or CR 3 Alpha Chain or Leukocyte Adhesion Receptor MO1 or Neutrophil Adherence Receptor or CD11b or ITGAM) Drugs in Development by Therapy Areas and...

May 2022 35 pages

Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) Drugs in Development by Therapy Areas an...

May 2022 52 pages

Interleukin 18 Receptor 1 (CD218 Antigen Like Family Member A or CDw218a or IL1 Receptor Related Protein or CD218a or IL18R1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Interleukin 18 Receptor 1 (CD218 Antigen Like Family Member A or CDw218a or IL1 Receptor Related Protein or CD218a or IL18R1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, M...

May 2022 39 pages

Interleukin 2 Receptor Subunit Beta (High Affinity IL 2 Receptor Subunit Beta or Interleukin 15 Receptor Subunit Beta or p70-75 or CD122 or IL2RB) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Interleukin 2 Receptor Subunit Beta (High Affinity IL 2 Receptor Subunit Beta or Interleukin 15 Receptor Subunit Beta or p70-75 or CD122 or IL2RB) Drugs in Development by Therapy Areas and Indications...

May 2022 58 pages

Interleukin 33 (Interleukin 1 Family Member 11 or IL1F11 or Nuclear Factor From High Endothelial Venules or NFHEV or IL33) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Interleukin 33 (Interleukin 1 Family Member 11 or IL1F11 or Nuclear Factor From High Endothelial Venules or NFHEV or IL33) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Mole...

May 2022 43 pages

Interleukin 6 (B Cell Stimulatory Factor 2 or BSF2 or CTL Differentiation Factor or CDF or Hybridoma Growth Factor or Interferon Beta 2 or IFNB2 or IL6) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Interleukin 6 (B Cell Stimulatory Factor 2 or BSF2 or CTL Differentiation Factor or CDF or Hybridoma Growth Factor or Interferon Beta 2 or IFNB2 or IL6) Drugs in Development by Therapy Areas and Indic...

May 2022 53 pages

Interleukin 6 Receptor Subunit Beta (Membrane Glycoprotein 130 or Oncostatin M Receptor Subunit Alpha or Interleukin 6 Signal Transducer or gp130 or CD130 or IL6ST) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Interleukin 6 Receptor Subunit Beta (Membrane Glycoprotein 130 or Oncostatin M Receptor Subunit Alpha or Interleukin 6 Signal Transducer or gp130 or CD130 or IL6ST) Drugs in Development by Therapy Are...

May 2022 37 pages

Isocitrate Dehydrogenase [NADP] Cytoplasmic (Oxalosuccinate Decarboxylase or Cytosolic NADP Isocitrate Dehydrogenase or IDP or NADP(+) Specific ICDH or IDH1 or EC 1.1.1.42) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Isocitrate Dehydrogenase [NADP] Cytoplasmic (Oxalosuccinate Decarboxylase or Cytosolic NADP Isocitrate Dehydrogenase or IDP or NADP(+) Specific ICDH or IDH1 or EC 1.1.1.42) Drugs in Development by The...

May 2022 42 pages

LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Mole...

May 2022 35 pages

Lanosterol 14 Alpha Demethylase (Sterol 14 Alpha Demethylase or Cytochrome P450 14DM or Cytochrome P450LI or Cytochrome P450 51A1 or CYPLI or CYP51A1 or EC 1.14.14.154) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Lanosterol 14 Alpha Demethylase (Sterol 14 Alpha Demethylase or Cytochrome P450 14DM or Cytochrome P450LI or Cytochrome P450 51A1 or CYPLI or CYP51A1 or EC 1.14.14.154) Drugs in Development by Therapy...

May 2022 57 pages

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) Drugs in Development by Therapy Areas and Indications, Stages, MoA, Ro...

May 2022 127 pages

Low Affinity Immunoglobulin Gamma Fc Region Receptor III A (Fc Gamma RIII Alpha or IgG Fc Receptor III-2 or CD16a or FCGR3A) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Low Affinity Immunoglobulin Gamma Fc Region Receptor III A (Fc Gamma RIII Alpha or IgG Fc Receptor III-2 or CD16a or FCGR3A) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Mo...

May 2022 40 pages

Lysyl Oxidase Homolog 2 (Lysyl Oxidase Like Protein 2 or Lysyl Oxidase Related Protein 2 or Lysyl Oxidase Related Protein WS9-14 or LOXL2 or EC 1.4.3.13) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Lysyl Oxidase Homolog 2 (Lysyl Oxidase Like Protein 2 or Lysyl Oxidase Related Protein 2 or Lysyl Oxidase Related Protein WS9-14 or LOXL2 or EC 1.4.3.13) Drugs in Development by Therapy Areas and Indi...

May 2022 37 pages

Mannan Binding Lectin Serine Protease 2 (Mannose Binding Protein Associated Serine Protease 2 or MBL Associated Serine Protease 2 or MASP2 or EC 3.4.21.104) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Mannan Binding Lectin Serine Protease 2 (Mannose Binding Protein Associated Serine Protease 2 or MBL Associated Serine Protease 2 or MASP2 or EC 3.4.21.104) Drugs in Development by Therapy Areas and I...

May 2022 39 pages

Membrane Primary Amine Oxidase (Copper Amine Oxidase or Semicarbazide-Sensitive Amine Oxidase or Vascular Adhesion Protein 1 or HPAO or AOC3 or EC 1.4.3.21) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Membrane Primary Amine Oxidase (Copper Amine Oxidase or Semicarbazide-Sensitive Amine Oxidase or Vascular Adhesion Protein 1 or HPAO or AOC3 or EC 1.4.3.21) Drugs in Development by Therapy Areas and I...

May 2022 43 pages

Mineralocorticoid Receptor (Nuclear Receptor Subfamily 3 Group C Member 2 or Mineralocorticoid Receptor Delta or Aldosterone Receptor or MR or NR3C2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Mineralocorticoid Receptor (Nuclear Receptor Subfamily 3 Group C Member 2 or Mineralocorticoid Receptor Delta or Aldosterone Receptor or MR or NR3C2) Drugs in Development by Therapy Areas and Indicati...

May 2022 41 pages

Monoglyceride Lipase (Lysophospholipase Homolog or Lysophospholipase Like or HU K5 or Monoacylglycerol Lipase or MGLL or EC 3.1.1.23) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Monoglyceride Lipase (Lysophospholipase Homolog or Lysophospholipase Like or HU K5 or Monoacylglycerol Lipase or MGLL or EC 3.1.1.23) Drugs in Development by Therapy Areas and Indications, Stages, MoA...

May 2022 38 pages

Filters

Search

Categories

209
1,199
32
238
214
187
155
140
64,297
1,312
1,311
2,468
184

Publishers

179
1
1,431
239
366
389
103
148
348
3
202
3
6
1,620
487
80
123
208
112
25
1,049
378
23
40
68
510
953
34
29,954
248
501
3,036
1
1
2
3
16
536
361
1
1,357
1,806
60
1,696
8
7,373
2,206
6,709
321
66
3
36
200
29
29
143
42
83
3
281
85
20
6
43
14
1
178
48
359
36
44
10
11
18
168
384
8
3
18
58
907
6
89
12
24
15
1,285
227
128
386
3
74
10
119
227
46
474
26
133
4

Regions

92
58
45
43
41
35
31
30
30
29
28
28
28
26
21
18
16
14
12
12
10
10
10
9
8
8
8
7
7
7
7
6
6
6
6
6
6
6
6
6
6
6
6
4
4
4
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
797
497
2
2
2
118
197
102
54
23
708
26
135
530
177
646
66,872

Price

—

Date

—

Pages

—

Offers

1
280
1
1